SREBF1 and fatty liver disease: Enhancing PPARα activity or inhibiting SREBP1c are effective strategies to mitigate liver steatosis and damage in obese and diabetic animals (Moslehi and Hamidi-Zad, 2018; Kusnadi et al., 2019; Zhou et al., 2019).